<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> is the most common <z:hpo ids='HP_0011675'>cardiac arrhythmia</z:hpo> responsible for a significant morbidity and mortality </plain></SENT>
<SENT sid="1" pm="."><plain>In recent years, progress has been made in determining the genetic abnormalities, the use of <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> as a component of a primary treatment strategy in many patients who have a high risk of recurrence and for <z:hpo ids='HP_0001907'>thromboembolism</z:hpo>, and newer and safer antiarrthythmics are now available </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this paper is to discuss about this topic and antiarrhythmic therapy </plain></SENT>
</text></document>